Send to

Choose Destination
Nat Struct Biol. 1998 Apr;5(4):276-9.

Capture of an early fusion-active conformation of HIV-1 gp41.

Author information

Office of Vaccines, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892-4555, USA.

Erratum in

  • Nat Struct Biol 1998 Jul;5(7):612.


Using an inhibitory synthetic peptide (DP-178) from HIV-1 gp41, we have trapped HIV-1 envelope glycoprotein (Env) undergoing conformational changes during virus entry. Our data show that DP-178 binds gp41 and inhibits Env-mediated membrane fusion after gp120 interacts with cellular receptors, indicating that conformational changes involving the coiled coil domain of gp41 are required for entry. Capture of this fusion-active conformation of Env provides insights into the early events leading to Env-mediated membrane fusion.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center